Lilly’s Jaypirca shows positive results in phase 3 trial - PharmaTimes Pirtobrutinib meets primary endpoint in CLL/SLL study

#oncology #Lilly #LillyOncology #Jaypirca #Pirtobrutinib #primaryendpoint #EliLilly #CLL313 #CLL314 #phase3 #BRUINCLL314trial #chroniclymphocyticleukaemia #CLL #smalllymphocyticlymphoma #SLL #noncovalentBTKinhibitor #Imbruvica #ibrutinib #covalentBTKinhibitor
pharmatimes.com/news/lillys-...